The use of proteomics in biomarker discovery in neurodegenerative diseases

Disease Markers

Volumn 21, Issue 2, 2005, Pages 81-92

  Davidsson, Pia ^a   Sjögren, Magnus ^a,b  

^a ASTRAZENECA R AND D   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer; Biomarkers; Cerebrospinal fluid; Diagnosis; Frontotemporal dementia neurodegenerative diseases; Parkinson's disease; Proteomics

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; DEGENERATIVE DISEASE; DEMENTIA; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NEUROPATHOLOGY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; PROTEIN VARIANT; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SYNAPSE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 21044437207     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2005/848676     Document Type: Article

References (106)

1. B. Akerstrom and L. Bjorck, A physicochemical study of protein G, a molecule with unique immunoglobulin G-binding properties, J Biol Chem 261 (1986), 10240-10247.
2. N. Andreasen, L. Minthon, A. Clarberg, P. Davidsson, J. Gottfries, E. Vanmechelen, H. Vanderstichele, B. Winblad and K. Blennow, Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample, Neurology 53 (1999), 1488-1494.
3. H. Arai, T. Satoh-Nakagawa, M. Higuchi, Y. Morikawa, M. Miura, H. Kawakami, H. Seki, S. Takase and H. Sasaki, No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia, Neurosci Lett 256 (1998), 174-176.
4. P. Bertrand, J. Poirier, T. Oda, C.E. Finch and G.M. Pasinetti, Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease, Brain Res Mol Brain Res 33 (1995), 174-178.
5. M. Bier, US Patent 4 588 492, 5-13-1986, 5-7-1984.
6. L. Bjorck and G. Kronvall, Purification and some properties of streptococcal protein G, a novel IgG-binding reagent, J Immunol 133 (1984), 969-974.
7. K. Björhall, T. Miliotis and P. Davidsson, Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples, Proteomics (2004), in press.
8. K. Blennow, P. Davidsson, A. Wallin, P. Fredman, C.G. Gottfries, J.E. Mansson and L. Svennerholm, Differences in cerebrospinal fluid gangliosides between "probable Alzheimer's disease" and normal aging, Aging 4 (1992), 301-306.
9. K. Blennow, C. Hesse and P. Fredman, Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease, Neuroreport 20 (1994), 2534-2536.
10. K. Blennow, A. Wallin, H. Agren, C. Spenger, J. Siegfried and E. Vanmechelen, Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26 (1995), 231-245.
11. K. Blennow, P. Davidsson, A. Wallin and R. Ekman, Chromogranin A in cerebrospinal fluid: a biochemical marker for synaptic degeneration in Alzheimer's disease? Dementia 6 (1995), 306-311.
12. K. Blennow, N. Bogdanovic, I. Alafuzoff, R. Ekman and P. Davidsson, Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele, J Neural Transm 103 (1996), 603-618.
13. N. Bogdanovic, P. Davidsson, I. Volkmann, B. Winblad and K. Blennow, Growth-associated protein GAP-43 in the frontal cortex and in the hippocampus in Alzheimer's disease: an immunohistochemical and quantitative study, J Neural Transm 107 (2000), 463-478.
14. M.D.P. Boyle, E.J. Siden and K.J. Reis, Selective colony blotting to expand bacterial surface receptors: applications to receptors for rat immunoglobulins, Biotechniques 6 (1988), 130-136.
15. L.E. Bradbury, J.F. LeBlanc and D.B. McCarthy, ProteinChip array-based amyloid beta assays, Methods Mol Biol 264 (2004), 245-257.
16. O. Carrette, I. Demalte, A. Scherl, O. Yalkinoglu, G. Corthals, P. Burkhard, D.F. Hochstrasser and J.C. Sanchez, A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease, Proteomics 3 (2003), 1486-1494.
17. L.H. Choe, L.H. Dutt, N. Relkin and K.H. Lee, Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease, Electrophoresis 23 (2002), 2247-2251.
18. E.H. Corder, A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. Small, A.D. Roses, J.L. Haines and M.A. Pericak-Vance, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science 13 (1993), 921-923.
19. P. Davidsson, R. Jahn, J. Bergquist, R. Ekman and K. Blennow, Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer disease? Mol Chem Neuropathol 2 (1996), 195-210.
20. P. Davidsson and K. Blennow, Neurochemical dissection of synaptic pathology in Alzheimer's disease, Int Psychogeriatr 1 (1998), 11-23.
21. P. Davidsson, M. Puchades and K. Blennow, Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing, Electrophoresis 20 (1999), 431-437.
22. P. Davidsson, A. Westman, M. Puchades, C.L. Nilsson and K. Blennow, Characterization of proteins from human cerebrospinal fluid by a combination of preparative two-dimensional liquid-phase electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, Anal Chem 1 (1999), 642-647.
23. P. Davidsson, L. Paulson, C. Hesse, K. Blennow and C.L. Nilsson, Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electrophoresis approach prior to mass spectrometry, Proteomics 3 (2001), 444-452.
24. P. Davidsson, S. Folkesson, M. Christiansson, M. Lindbjer, B. Dellheden, K. Blennow and A. Westman-Brinkmalm, Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry, Rapid Commun Mass Spectrom 16 (2002), 2083-2088.
25. P. Davidsson, A. Westman-Brinkmalm, C.L. Nilsson, M. Lindbjer, L. Paulson, N. Andreasen, M. Sjogren and K. Blennow, Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients, Neuroreport 13 (2002), 611-615.
26. P. Davidsson, M. Sjogren, N. Andreasen, M. Lindbjer and C.L. Nilsson, A. Westman-Brinkmalm and K. Blennow, Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins, Brain Res Mol Brain Res 109 (2002), 128-133.
27. C.A. Davies, D.M. Mann, P.Q. Sumpter and P.O. Yates, A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease, J Neurol Sci 78 (1987), 151-164.
28. S.T. DeKosky and S.W. Scheff, Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity, Ann Neurol 5 (1990), 457-464.
29. J.M. Dietschy and S.D. Turley, Cholesterol metabolism in the brain, Curr Opin Lipidol 12 (2001), 105-112.
30. N.A. Elshourbagy, W.S. Liao, R.W. Mahley and J.M. Taylor, Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets, Proc Natl Acad Sci USA 82 (1985), 203-207.
31. L.A. Farrer, L.A. Cupples J.L. Haines, B. Hyman, W.A. Kukull, R. Mayeux, R.H. Myers, M.A. Pericak-Vance, N. Risch and C.M. van Duijn, Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium, JAMA 278 (1997), 1349-1356.
32. S. Folkesson Hansson, M. Puchades, K. Blennow, M. Sjogren and P. Davidsson, Validation of a prefractionation method followed by two-dimensional electrophoresis - Applied to cerebrospinal fluid proteins from frontotemporal dementia patients, Proteome Sci 2 (2004), 7-21.
33. A. Fonteh and M. Harrington, Importance of proteins that metabolite polyunsaturated fatty acids in the pathogenesis of Alzheimer's disease, In 5th Siena meeting, from genome to proteome: functional proteomics, 2002, Italy.
34. D. Galasko, L. Chang, R. Motter, C.M. Clark, J. Kaye, D. Knopman, R. Thomas, D. Kholodenko, D. Schenk, I. Lieberburg, B. Miller, R. Green, R. Basherad, L. Kertiles, M.A. Boss and P. Seubert, High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype, Arch Neurol 55 (1998), 937-945.
35. E. Gianazza and P. Arnaud, A general method for fractionation of plasma proteins. Dye-ligand affinity chromatography on immobilized Cibacron blue F3-GA, J Biochem 203 (1982), 637-641.
36. J. Gottfries, M. Sjögren, B. Holmberg, L. Rosengren, P. Davidsson and K. Blennow, Proteomics for drug target discovery, Chemomatrics and Intelligent Laboratory Systems (2004), in press.
37. N.I. Govorukhina, A. Keizer-Gunnink, A.G.J. van der Zee, S. de Jong, H.W.A. de Bruijn and R. Bischoff, J Chrom A 1009 (2003), 171-178.
38. S. Greber, G. Lubec, N. Cairns and M. Fountoulakis, Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer's disease, Electrophoresis 20 (1999), 928-934.
39. A.J. Green, R.J. Harvey, E.J. Thompson and M.N. Rossor, Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease, Neurosci Lett 259 (1999), 133-135.
40. J.E. Hamos, L.J. DeGennaro and D.A. Drachman, Synaptic loss in Alzheimer's disease and other dementias, Neurology 39 (1989), 355-361.
41. S. Hanash, F. Brichory and D. Beer, A proteomic approach to the identification of lung cancer markers, Dis Markers 17 (2001), 295-300.
42. K. Hakansson, M.R. Emmett, A.G. Marshall, P. Davidsson and C.L. Nilsson, Structural analysis of 2D-gel-separated glycoproteins from human cerebrospinal fluid by tandem high-resolution mass spectrometry, J Proteome Res 2 (2003), 581-588.
43. S.D. Harr, L. Uint, R. Hollister, B.T. Hyman and A.J. Mendez, Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease, J Neurochem 66 (1996), 2429-2435.
44. M.G. Harrington and C.R. Merril, Two-dimensional electrophoresis and "ultrasensitive" silver staining of cerebrospinal fluid proteins in neurological diseases, Clin Chem 30 (1984), 1933-1937.
45. M.G. Harrington, C.R. Merril and E.F. Torrey, Differences in cerebrospinal fluid proteins between patients with schizophrenia and normal persons, Clin Chem 31 (1985), 722-726.
46. M.G. Harrington and Y.P.G. Kennedy, The clinical use of cerebrospinal fluid studies in demyelinating neurological diseases, Postgrad Med J 63 (1987), 735-740.
47. M.G. Harrington and C.R. Merril, Cerebrospinal fluid protein analysis in diseases of the nervous system, J Chromatogr 429 (1988), 345-358.
48. C. Hesse, N. Bogdanovic, P. Davidsson and K. Blennow, A quantitative and immunohistochemical study on apolipoprotein E in brain tissue in Alzheimer's disease, Dement Geriatr Cogn Disord 6 (1999), 452-459.
49. C. Hesse, L. Rosengren, E. Vanmechelen, H. Vanderstichele, C. Jensen, P. Davidsson and K. Blennow, Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke, J Alzheimers Dis 2 (2000), 199-206.
50. C. Hesse, H. Larsson, P. Fredman, L. Minthon, N. Andreasen, P. Davidsson and K. Blennow, Measurement of apolipoprotein E (apoE) in cerebrospinal fluid, Neurochem Res 25 (2000), 511-517.
51. C. Hesse, L. Rosengren, N. Andreasen, P. Davidsson, H. Vanderstichele, E. Vanmechelen and K. Blennow, Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neurosci Lett 297 (2001), 187-190.
52. C. Hesse, C.L. Nilsson, K. Blennow and P. Davidsson, Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionization- time of flight-mass spectrometry, Electrophoresis 22 (2001), 1834-1837.
53. C. Hock, S. Golombowski, F. Muller-Spahn, W. Naser, K. Beyreuther, U. Monning, D. Schenk, C. Vigo-Pelfrey, A.M. Bush, R. Moir, R.E. Tanzi, J.H. Growdon and R.M. Nitsch, Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression - inverse correlation with dementia severity, Eur Neurol 39 (1998), 111-118.
54. F. Hulstaert, K. Blennow, A. Ivanoiu, H.C. Schoonderwaldt, M. Riemenschneider M, P.P. De Deyn, C. Bancher, P. Cras, J. Wiltfang, P.D. Mehta, K. Iqbal, H. Pottel, E. Vanmechelen and H. Vanderstichele, Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF, Neurology 52 (1999), 1555-1562.
55. N. Ida, T. Hartmann, J. Pantel, J. Schroder, R. Zerfass, H. Forstl, R. Sandbrink, C.L. Masters and K. Beyreuther, Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay, J Biol Chem 271 (1996), 22908-22914.
56. H. Idborg-Bjorkman, P.O. Edlund, O.M. Kvalheim, I. Schuppe-Koistinen and S.P. Jacobsson, Screening of biomarkers in rat urine using LC/electrospray ionization-MS and two-way data analysis, Anal Chem 75 (2003), 4784-4792.
57. M. Jensen, J. Schroder, M. Blomberg, B. Engvall, J. Pantel, N. Ida, H. Basun, L.O. Wahlund, E. Werle, M. Jauss, K. Beyreuther, L. Lannfelt and T. Hartmann, Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression, Ann Neurol 45 (1999), 504-511.
58. M.B. Jones, H.J. Krutzsch, H.J. Shu, Y.M. Zhao, L.A. Liotta, E.C. Kohn and E.F. Petricoin, Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer, Proteomics 2 (2002), 76-84.
59. D. Lefranc, P. Vermersch, J. Dallongeville, C. Daems-Monpeurt, H. Petit and A. Delacourte, Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease, Neurosci Lett 212 (1996), 91-94.
60. M. Landen, C. Hesse, P. Fredman, B. Regland, A. Wallin and K. Blennow, Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform, Dementia 7 (1996), 273-278.
61. P. Lewczuk, H. Esselmann, T.W. Groemer, M. Bibl, J.M. Maler, P. Steinacker, M. Otto, J. Kornhuber and J. Wiltfang, Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease, Biol Psychiatry 55 (2004), 524-530.
62. A.M. Lidstrom, C. Hesse, L. Rosengren, P. Fredman, P. Davidsson and K. Blennow, Normal levels of clusterin in cerebrospinal fluid in Alzheimer's disease, and no change after acute ischemic stroke, J Alzheimers Dis 3 (2001), 435-442.
63. R.W. Mahley, Apolipoprotein E: cholesterol transport protein with expanding role in cell biology, Science 240 (1988), 622-630.
64. C.L. Masters, G. Simms, N.A. Weinman, G. Multhaup, B.L. McDonald and K. Beyreuther, Amyloid plaque core protein in Alzheimer disease and Down syndrome, Proc Natl Acad Sci USA 82 (1985), 4245-1249.
65. W.H. McDonald and J.R. Yates, Shotgun proteomics and biomarker discovery, Dis. Markers 18 (2002), 99-105.
66. A. Merched, J.M. Serot, S. Visvikis, D. Aguillon, G. Faure and G. Sies, Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry, FEBS Lett 425 (1998), 225-228.
67. A. Merched, Y. Xia, S. Visvikis, J.M. Serot and G. Siest, Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease, Neurobiol Aging 1 (2000), 7-30.
68. C.R. Merril and M.G. Harrington, "Ultrasensitive" silver stains: their use exemplified in the study of normal human cerebrospinal fluid proteins separated by two-dimensional electrophoresis, Clin Chem 30 (1984), 1938-1942.
69. L. Molina, J. Touchon, M. Herpe, D. Lefranc, L. Duplan, J.P. Cristol, R. Sabatier, P. Vermersch, B. Pau and C. Mourton-Gilles, Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias, Neuroreport 10 (1999), 3491-3495.
70. C.L. Nilsson, M. Puchades, A. Westman, K. Blennow and P. Davidsson, Identification of proteins in a human pleural exudate using two-dimensional preparative liquid-phase electrophoresis and matrix-assisted laser desoiption/ionization mass spectrometry, Electrophoresis 20 (1999), 860-865.
71. A. Olsson, K. Hoglund, M. Sjogren, N. Andreasen, L. Minthon, L. Lannfelt, K. Buerger, H.J. Moller, H. Hampel, P. Davidsson and K. Blennow, Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients, Exp Neurol 183 (2003), 74-80.
72. M.R. Palmert, M. Usiak, R. Mayeux, M. Raskind, W.W. Tourtellotte and S.G. Younkin, Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease, Neurology 40 (1990), 1028-1034.
73. J.M. Pasternack, M.R. Palmert, M. Usiak, R. Wang, H. Zurcher-Neely, P.A. Gonzalez-De Whitt, M.B. Fairbanks, T. Cheung, D. Blades and R.L. Heinrikson, Alzheimer's disease and control brain contain soluble derivatives of the amyloid protein precursor that end within the beta amyloid protein regio, Biochemistry 10 (1992), 10936-10940.
74. C.P. Paweletz, B. Trock, M. Pennanen, T. Tsangaris, C. Magnant L.A. Liotta and E.F. Petricoin, Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer, Dis Markers 17 (2001), 301-307.
75. E.F. Petricoin, A.M. Ardekani, B.A. Hitt, P.J. Levine, V.A. Fusaro, S.M. Steinberg, G.B. Mills, C. Simone, D.A. Fishman, E.C. Kohn and L.A. Liotta, Use of proteomic patterns in serum to identify ovarian cancer, Lancet 359 (2002), 572-577.
76. R. Pieper, C.L. Gatlin, A.J. Makusky, P.S. Russo, C.R. Schatz, S.S. Miller, Q. Su, A.M. McGrath, M.A. Estock, P.P. Parmar, M. Zhao, S.T. Huang, J. Zhou, F. Wang, R. Esquer-Blasco, N.L. Anderson, J. Taylor and S. Steiner, The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins, Proteomics 3 (2003), 1345-1364.
77. T. Pirttila, K.S. Kim, P.D. Mehta, H. Frey and H.M. Wisniewski, Soluble amyloid beta-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls, J Neurol Sci 127 (1994), 90-95.
78. T. Pirttila, P.D. Mehta, H. Soininen, K.S. Kim, O. Heinonen, L. Paljarvi, O. Kosunen, P.S.R. Riekkinen and H.M. Wisniewski, Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain, Arch Neurol 53 (1996), 189-193.
79. R.E. Pitas, J.K. Boyles, S.H. Lee, D. Foss and R.W. Mahley, Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins, Biochim Biophys Acta 917 (1987), 148-161.
80. R. Prior, U. Monning, U. Schreiter-Gasser, A. Weidemann, K. Blennow, C.G. Gottfries, C.L. Masters and K. Beyreuther, Quantitative changes in the amyloid beta A4 precursor protein in Alzheimer cerebrospinal fluid, Neurosci Lett 124 (1991), 69-73.
81. M. Puchades, S.F. Hansson, C.L. Nilsson, N. Andreasen, K. Blennow and P. Davidsson, Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease, Brain Res Mol Brain Res 118 (2003), 140-146.
82. M. Puchades, Development of proteomic methods for studying cerebrospinal fluid proteins in Alzheimer's disease, 2003, thesis, University of Göteborg.
83. G.W. Rebeck, S.D. Harr, D.K. Strickland and B.T. Hyman, Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein, Ann Neurol 37 (1995), 211-217.
84. A.D. Roses, Apolipoprotein E alleles as risk factors in Alzheimer's disease, Annu Rev Med 47 (1996), 387-400.
85. A.M. Saunders, W.J. Strittmatter, D. Schmechel, P.H. George-Hyslop, M.A. Pericak-Vance, S.H. Joo, B.L. Rosi, J.F. Gusella, D.R. Crapper-MacLachlan, M.J. Alberts et al., Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease, Neurology 43 (1993), 1467-1472.
86. G. Schlaf, C. Salje, A. Wetter, K. Stuertz, K. Felgenhauer and M. Mader, Determination of synapsin I and synaptophysin in body fluids by two-site enzyme-linked immunosorbent assays, J Immunol Methods 213 (1998), 191-199.
87. P. Seubert, C. Vigo-Pelfrey, F. Esch, M. Lee, H. Dovey, D. Davis, S. Sinha, M. Schlossmacher, J. Whaley, C. Swindlehurst et al., Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids, Nature 359 (1992), 325-327.
88. P. Seubert, T. Oltersdorf, M.G. Lee, R. Barbour, C. Blomquist, D.L. Davis, K. Bryant, L.C. Fritz, D. Galasko and L.J. Thal, Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide, Nature 361 (1993), 260-263.
89. A. Sickmann, W. Dormeyer, S. Wortelkamp, D. Woitallad, W. Kuhn and H.E. Meyer, Identification of proteins from human cerebrospinal fluid, separated by two-dimensional polyacrylamide gel electrophoresis, Electrophoresis 21 (2000), 2721-2728.
90. M. Sjogren, L. Minthon, P. Davidsson, A.K. Granerus, A. Clarberg, H. Vanderstichele, E. Vanmechelen, A. Wallin and K. Blennow, CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging, J Neural Transm 107 (2000), 563-579.
91. M. Sjogren, P. Davidsson, M. Tullberg, L. Minthon, A. Wallin, C. Wikkelso, A.K. Granerus, H. Vanderstichele, E. Vanmechelen and K. Blennow, Both total and phosphorylated tau are increased in Alzheimer's disease, J Neurol Neurosurg Psychiatry 70 (2001), 624-630.
92. M. Sjogren, P. Davidsson, J. Gottfries, H. Vanderstichele, A. Edman, E. Vanmechelen, A. Wallin and K. Blennow, The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process, Dement Geriatr Cogn Disord 12 (2001), 257-264.
93. L.F. Steel, M.G. Trotter, P.B. Nakajima, T.S. Mattu, G. Gonye and T. Block, Efficient and specific removal of albumin from human serum samples, Molecular and Cellular Proteomics 2 (2003), 262-270.
94. W.J. Strittmatter, A.M. Saunders, D. Schmechel, M. Pericak-Vance, J. Enghild, G.S. Salvesen and A.D. Roses, Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease, Proc Natl Acad Sci USA 90 (1993), 1977-1981.
95. C.I. Sze, H. Bi, B.K. Kleinschmidt-DeMasters, C.M. Filley and L.J. Martin, Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer's disease brains, J Neurol Sci 175 (2000), 81-90.
96. M. Takashima, Y. Kuramitsu, Y. Yokoyama, N. Iizuka, T. Toda, I. Sakaida, K. Okita, M. Oka and K. Nakamura, Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma, Proteomics 3 (2003), 2487-2493.
97. R.D. Terry, E. Masliah, D.P. Salmon, N. Butters, R. DeTeresa, R. Hill, L.A. Hansen and R. Katzman, Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment, Ann Neurol 4 (1991), 572-580.
98. T. Uchihara, C. Duyckaerts, Y. He, K. Kobayashi, D. Seilhean, P. Amouyel and J.J. Hauw, ApoE immunoreactivity and microglial cells in Alzheimer's disease brain, Neurosci Lett 195 (1995), 5-8.
99. M. Vandermeeren, M. Mercken, E. Vanmechelen, J. Six, A. van de Voorde, J.J. Martin and P. Cras, Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay, J Neurochem 61 (1993), 1828-1834.
100. Y.Y. Wang, P. Cheng and D.W. Chan, A simple affinity spin tube filter method for removing high-abundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis, Proteomics 3 (2003), 243-248.
101. W.E. Van Nostrand, S.L. Wagner, W.R. Shankle, J.S. Farrow, M. Dick, J.M. Rozemuller, M.A. Kuiper, E.C. Wolters, J. Zimmerman and C.W. Cotman, Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients, Proc Natl Acad Sci USA 89 (1992), 2551-2555.
102. B.R. Wenner, M.A. Lovell and B.C. Lynn, Proteomic analysis of human ventricular cerebrospinal fluid from neurologically normal, elderly subjects using two-dimensional LC-MS/MS, J Proteome Res 3 (2004), 97-103.
103. C. Vigo-Pelfrey, D. Lee, P. Keim, I. Lieberburg and D.B. Schenk, Characterization of beta-amyloid peptide from human cerebrospinal fluid, J Neurochem 61 (1993), 1965-1968.
104. C. Vigo-Pelfrey, P. Seubert, R. Barbour, C. Blomquist, M. Lee, D. Lee, F. Coria, L. Chang, B. Miller, I. Lieberburg et al., Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease, Neurology 45 (1995), 788-793.
105. J. Wiltfang, H. Esselmann, M. Bibl, A. Smirnov, M. Otto, S. Paul, B. Schmidt, H.W. Klafki, M. Maler, T. Dyrks, M. Bienert, M. Beyermann, E. Ruther and J. Kornhuber, Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation, J Neurochem 81 (2002), 481-496.
106. X. Yuan, T. Russell, G. Wood and M. Desiderio, Analysis of the human lumbar cerebrospinal fluid proteome, Electrophoresis 23 (2002), 1185-1196.